184 related articles for article (PubMed ID: 32988149)
1. [Expert consensus on assessing tumor response to immune checkpoint inhibitors by PET/CT (2020 Edition)].
PET Group, Chinese Society of Nuclear Medicine
Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):697-705. PubMed ID: 32988149
[TBL] [Abstract][Full Text] [Related]
2. Interpretation of 2-[
Manson G; Lemchukwu AC; Mokrane FZ; Lopci E; Aide N; Vercellino L; Houot R; Dercle L
Eur Radiol; 2022 Sep; 32(9):6536-6544. PubMed ID: 35344061
[TBL] [Abstract][Full Text] [Related]
3. PET/CT molecular imaging in the era of immune-checkpoint inhibitors therapy.
Gao Y; Wu C; Chen X; Ma L; Zhang X; Chen J; Liao X; Liu M
Front Immunol; 2022; 13():1049043. PubMed ID: 36341331
[TBL] [Abstract][Full Text] [Related]
4. FDG PET/CT for assessing tumour response to immunotherapy : Report on the EANM symposium on immune modulation and recent review of the literature.
Aide N; Hicks RJ; Le Tourneau C; Lheureux S; Fanti S; Lopci E
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):238-250. PubMed ID: 30291373
[TBL] [Abstract][Full Text] [Related]
5.
Prigent K; Aide N
PET Clin; 2020 Jan; 15(1):1-10. PubMed ID: 31735296
[TBL] [Abstract][Full Text] [Related]
6. Assessment of early metabolic progression in melanoma patients under immunotherapy: an
Sachpekidis C; Kopp-Schneider A; Hassel JC; Dimitrakopoulou-Strauss A
EJNMMI Res; 2021 Sep; 11(1):89. PubMed ID: 34495433
[TBL] [Abstract][Full Text] [Related]
7.
Cherk MH; Nadebaum DP; Barber TW; Beech P; Haydon A; Yap KS
J Med Imaging Radiat Oncol; 2022 Jun; 66(4):483-494. PubMed ID: 35191204
[No Abstract] [Full Text] [Related]
8. Imaging assessment of toxicity related to immune checkpoint inhibitors.
Berz AM; Boughdad S; Vietti-Violi N; Digklia A; Dromain C; Dunet V; Duran R
Front Immunol; 2023; 14():1133207. PubMed ID: 36911692
[TBL] [Abstract][Full Text] [Related]
9. Imaging the Cancer Immune Environment and Its Response to Pharmacologic Intervention, Part 2: The Role of Novel PET Agents.
Iravani A; Hicks RJ
J Nucl Med; 2020 Nov; 61(11):1553-1559. PubMed ID: 32887755
[TBL] [Abstract][Full Text] [Related]
10. Immune PET Imaging.
Iyalomhe O; Farwell MD
Radiol Clin North Am; 2021 Sep; 59(5):875-886. PubMed ID: 34392924
[TBL] [Abstract][Full Text] [Related]
11.
Ito K; Teng R; Schöder H; Humm JL; Ni A; Michaud L; Nakajima R; Yamashita R; Wolchok JD; Weber WA
J Nucl Med; 2019 Mar; 60(3):335-341. PubMed ID: 30413661
[TBL] [Abstract][Full Text] [Related]
12. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
13. Update on tumor metabolism and patterns of response to immunotherapy.
Castello A; Lopci E
Q J Nucl Med Mol Imaging; 2020 Jun; 64(2):175-185. PubMed ID: 32107904
[TBL] [Abstract][Full Text] [Related]
14. Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe).
Nanni C; Versari A; Chauvie S; Bertone E; Bianchi A; Rensi M; Bellò M; Gallamini A; Patriarca F; Gay F; Gamberi B; Ghedini P; Cavo M; Fanti S; Zamagni E
Eur J Nucl Med Mol Imaging; 2018 May; 45(5):712-719. PubMed ID: 29270787
[TBL] [Abstract][Full Text] [Related]
15. FDG PET/CT for Assessment of Immune Therapy: Opportunities and Understanding Pitfalls.
Cho SY; Huff DT; Jeraj R; Albertini MR
Semin Nucl Med; 2020 Nov; 50(6):518-531. PubMed ID: 33059821
[TBL] [Abstract][Full Text] [Related]
16. [Chinese multidisciplinary expert consensus on combined immunotherapy based on immune checkpoint inhibitors for hepatocellular carcinoma(2021 version)].
; ;
Zhonghua Gan Zang Bing Za Zhi; 2021 Jul; 29(7):636-647. PubMed ID: 34371534
[TBL] [Abstract][Full Text] [Related]
17. Expert Consensus on clinical application of FDG PET/CT in infection and inflammation.
Li Y; Wang Q; Wang X; Li X; Wu H; Wang Q; Yao Z; Miao W; Zhu X; Hua F; Zhang X; Cheng C; Zhang W; Hou Q; Li Y; Li XF
Ann Nucl Med; 2020 May; 34(5):369-376. PubMed ID: 32086761
[TBL] [Abstract][Full Text] [Related]
18. The Role of PET/CT in the Era of Immune Checkpoint Inhibitors: State of Art.
Castello A; Lopci E
Curr Radiopharm; 2020; 13(1):24-31. PubMed ID: 31749440
[TBL] [Abstract][Full Text] [Related]
19. Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point
Cho SY; Lipson EJ; Im HJ; Rowe SP; Gonzalez EM; Blackford A; Chirindel A; Pardoll DM; Topalian SL; Wahl RL
J Nucl Med; 2017 Sep; 58(9):1421-1428. PubMed ID: 28360208
[TBL] [Abstract][Full Text] [Related]
20. Immune-mediated Disease in Ipilimumab Immunotherapy of Melanoma with FDG PET-CT.
Wachsmann JW; Ganti R; Peng F
Acad Radiol; 2017 Jan; 24(1):111-115. PubMed ID: 27818005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
